Semaglutide patents extend through the late 2020s-2030s depending on jurisdiction and formulation. Tirzepatide patents are newer and extend further. Biosimilar development for injectable peptides is more complex than traditional generics—it requires demonstrating bioequivalence through clinical trials. Some biosimilar development is underway internationally, and semaglutide generics may appear in certain countries before the U.S. The gray market and compounding pharmacies currently fill the affordability gap, but true FDA-approved generics are likely years away.